🏛️ Verified NIH Record • Updated 2026-08-10
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (NCT02436707)
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Canadian Cancer Trials Group
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.
Who can join: Review the eligibility criteria below.
Location: Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Age range: 16 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- BCCA - Vancouver — Vancouver, British Columbia
- CancerCare Manitoba — Winnipeg, Manitoba
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Kingston Health Sciences Centre — Kingston, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- University Health Network — Toronto, Ontario
- CHUM-Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
- CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) — Québec, Quebec
- Allan Blair Cancer Centre — Regina, Saskatchewan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
- A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma — Anchorage, Alaska
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant — New York, New York
- Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL — Chapel Hill, North Carolina
Explore by condition: All Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.